Fresh Tracks Therapeutics Inc

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Fresh Tracks Therapeutics, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in September 2009 and is headquartered in Boulder, CO.

Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court Company filed an answer in overall agreement with petition on June 14, 2024 and awaits a hearing date from the Delaware Chancery Court

Fresh Tracks Therapeutics Announces Delaware Petition Filed Seeking Appointment of Custodian for Eventual Dissolution of Company

Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024

Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th

New record date expected to be January 11, 2024 Company intends to seek judicial dissolution if the liquidation and dissolution is not approved by Fresh Tracks' stockholders at new special meeting, which would reduce the amount of cash distributable to stockholders BOULDER, Colo., Dec. 27, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (Nasdaq: FRTX) (“Fresh Tracks” or the “Company”) announced today plans to hold a new special meeting of stockholders on February 15, 2024 (the “Special Meeting”) to seek stockholder approval of the liquidation and dissolution of the Company (the “Dissolution”) and the plan of liquidation and dissolution (the “Plan of Dissolution”).

Fresh Tracks Therapeutics Announces Plan to Hold New Special Meeting of Stockholders on February 15th

BOULDER, Colo., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (OTC Pink: FRTX) (“Fresh Tracks” or the “Company”) announced today that the Company's common stock was suspended from trading on The Nasdaq Capital Market at the open of business. Following the suspension, the Company's common stock now is quoted on the OTC Pink market under the same trading symbol, “FRTX.” The Company has withdrawn its appeal of Nasdaq's determination to delist the Company's common stock, which will no longer trade on The Nasdaq Capital Market.

Fresh Tracks Therapeutics Announces Listing on OTC Pink Market

Common stock expected to begin trading on over-the-counter market following suspension Common stock expected to begin trading on over-the-counter market following suspension

Fresh Tracks Therapeutics Announces its Common Stock will be Suspended from Trading on Nasdaq at Open of Business on December 19th

Meeting adjourned to December 27, 2023 at 10 a.m. MT

Fresh Tracks Therapeutics Announces Third Adjournment of Special Meeting of Stockholders

Brickell Biotech Inc

Meeting adjourned to December 15, 2023 at 10 a.m. MT

Fresh Tracks Therapeutics Announces Second Adjournment of Special Meeting of Stockholders

Meeting adjourned to November 30, 2023 at 10 a.m. MT Fresh Tracks encourages all stockholders of record on October 17, 2023 who have not yet voted to do so by 11:59 p.m.

Fresh Tracks Therapeutics Announces Adjournment of Special Meeting of Stockholders

Cash and cash equivalents of approximately $11.5 million as of October 31, 2023 Special meeting of stockholders on November 16 seeking stockholder approval of the Dissolution and Plan of Dissolution If approved by stockholders, the Company estimates that cash distributions in the Dissolution will be between $5 million and $7 million, or $0.84 to $1.17 per share, to stockholders BOULDER, Colo., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (the “Company” or “Fresh Tracks”) (Nasdaq: FRTX), today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.

Fresh Tracks Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution Company intends to make cash distributions currently estimated to be between $5 million and $7 million, or $0.84 to $1.17 per share, to shareholders following shareholder approval and the filing of the certificate of dissolution

Fresh Tracks Therapeutics Announces Board Approval of Plan of Liquidation and Dissolution

Biocept

Moderna

Sonnet BioTherapeutics

TRACON Pharmaceuticals

Tenax Therapeutics

Windtree Therapeutics

Investing in biotech stocks can be challenging. The rewards can be great when your company hits on a popular drug, treatment or product.

7 F-Rated Biotech Stocks You Shouldn't Touch With a 10-Foot Pole

Strengthened current cash position to approximately $15 million as of July 31, 2023 as a result of sale of future rights to event-based milestone and earnout payments on net sales of sofpironium bromide to Botanix SB Inc.

Fresh Tracks Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder value

Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix

Reported positive topline results from SAD and MAD parts of Phase 1 study of lead DYRK1A inhibitor FRTX-02 in March 2023

Fresh Tracks Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Positive topline results from single and multiple ascending dose parts of the Phase 1 study of FRTX-02 support its continued development as a potential first-in-class, once-daily oral treatment for atopic dermatitis and/or other autoimmune diseases

Fresh Tracks Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Fresh Tracks Therapeutics (NASDAQ: FRTX ) stock is heading higher on Wednesday after announcing positive results from a Phase 1 clinical trial. That clinical trial covers the use of FRTX-02 to restore immunity balance.

Why Is Fresh Tracks Therapeutics (FRTX) Stock Up 92% Today?

FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives

Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02

Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company Rob Brown to continue serving as a member of the Board of Directors and as a special advisor to the Company

Fresh Tracks Therapeutics Appoints Andrew Sklawer as Chief Executive Officer

Aprea Therapeutics

Bionano Genomics

Eton Pharmaceuticals Inc

4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks To Buy? 4 To Watch In January 2023

Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023 Topline results from SAD and MAD parts of FRTX-02 Phase 1 study expected in Q1 2023

Fresh Tracks Therapeutics Announces Publication of Preclinical Data for FRTX-02, a Potential First-in-Class Oral DYRK1A Inhibitor, in the Peer-Reviewed Journal of Translational Autoimmunity

Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Garth Russell - LifeSci Advisors Robert Brown - CEO Monica Luchi - Chief Medical Officer Albert Marchio - CFO Conference Call Participants Tim Lugo - William Blair Thomas Flaten - Lake Street Capital Operator Welcome everyone, to the Fresh Tracks Therapeutics Third Quarter 2022 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call is being recorded.

Fresh Tracks Therapeutics, Inc. (FRTX) Q3 2022 Earnings Call Transcript

Fresh Tracks Therapeutics (FRTX) delivered earnings and revenue surprises of -9.52% and 56.77%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Fresh Tracks Therapeutics (FRTX) Reports Q3 Loss, Tops Revenue Estimates

Phase 1 study of FRTX-02 progressing well, with the SAD portion complete and MAD portion underway

Fresh Tracks Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

BOULDER, Colo., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc. (“Fresh Tracks Therapeutics” or the “Company”) (Nasdaq: FRTX), a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases, today announced that it will report its third quarter financial results on Thursday, November 10th. Company management will host a conference call and webcast at 4:30 p.m. EST that same day to discuss the financial results and recent corporate highlights.

Fresh Tracks Therapeutics to Report Third Quarter 2022 Financial Results and Provide a Corporate Update on November 10, 2022

FRTX-02 has been well tolerated in completed SAD cohorts; dosing of remaining SAD cohorts to continue in parallel with MAD cohorts dosing

News for Fresh Tracks Therapeutics Inc Stock (FRTX)